Company / Current Assets
Rein Therapeutics, Inc. Current Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$4.3M
FY2025
5-year range
$4.3M / $48.2M
FY2021-FY2025
Trend
-68.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has declined for 4 consecutive years, from $48M in FY2021 to $4M in FY2025.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -23.3%.
Declined from $18M to $4M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -41.7%
- 5-Year CAGR
- -23.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Rein Therapeutics, Inc.'s current assets has declined for 4 consecutive years.
- 5-year CAGR of -23.3%, indicating a declining trend.
- In FY2025, current assets decreased 68.3% year-over-year.
- Peak current assets was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.3M | -68.3% |
| FY2024 | $13.7M | -25.2% |
| FY2023 | $18.3M | -16.5% |
| FY2022 | $21.9M | -54.6% |
| FY2021 | $48.2M | +195.1% |
| FY2020 | $16.3M | -16.5% |
| FY2019 | $19.6M | -10.2% |
| FY2018 | $21.8M | -58.0% |
| FY2017 | $51.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026